Class of 2007 AbstractObjectives: The objective of this study was to determine the cost-effectiveness of using the Invader® UGT1A1 Molecular Assay to identify patients at risk of experiencing neutropenia from irinotecan monotherapy and FOLFIRI. Methods: Publicly available search engines were used to search for literature reporting the rate, treatment, and cost of adverse events and the population rate of genotypes. Drug acquisition costs were determined using average wholesale prices. Additional costs were determined using the Physicians’ Fee and Coding Guide. Monte Carlo Simulations were performed to reveal average cost, average effectiveness, and 95% confidence intervals. Tornado diagrams were derived to identify variables most likely to ...
BackgroundChemotherapy-induced nausea and vomiting are concerning adverse events resulting from canc...
Objectives The study aims at evaluating the economic evidence related to testing for genetic varian...
BackgroundChemotherapy-induced nausea and vomiting are concerning adverse events resulting from canc...
ABSTRACT – Purpose. Functional polymorphisms of the UGT1A1 gene, particularly the UGT1A1*28 variant,...
The adoption of a pre-emptive UGT1A1*28 genotyping to increase irinotecan safety in clinical practic...
Aim: To determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosi...
BACKGROUND: The evidence concerning the cost-effectiveness of UGT1A1*28 genotyping is ambiguous and ...
<p><b>Background.</b> The evidence concerning the cost-effectiveness of UGT1A1*28 genotyping is ambi...
Background: Pre-therapeutic UGT1A1 genotyping is not yet routinely performed in most hospitals in pa...
Only a few studies have addressed the cost-effectiveness of pharmacogenetics interventions in health...
Current guidelines recommend pre-therapeutic UGT1A1 genotyping to guide irinotecan dosing, but the u...
Only a few studies have addressed the cost-effectiveness of pharmacogenetics interventions in health...
Objective. To determine whether prospective testing forHLA-B*58:01, as a strategy to preve...
BACKGROUND: Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), caused by allopurin...
The overall goal of this study was to provide evidence for the clinical validity of nine genetic var...
BackgroundChemotherapy-induced nausea and vomiting are concerning adverse events resulting from canc...
Objectives The study aims at evaluating the economic evidence related to testing for genetic varian...
BackgroundChemotherapy-induced nausea and vomiting are concerning adverse events resulting from canc...
ABSTRACT – Purpose. Functional polymorphisms of the UGT1A1 gene, particularly the UGT1A1*28 variant,...
The adoption of a pre-emptive UGT1A1*28 genotyping to increase irinotecan safety in clinical practic...
Aim: To determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosi...
BACKGROUND: The evidence concerning the cost-effectiveness of UGT1A1*28 genotyping is ambiguous and ...
<p><b>Background.</b> The evidence concerning the cost-effectiveness of UGT1A1*28 genotyping is ambi...
Background: Pre-therapeutic UGT1A1 genotyping is not yet routinely performed in most hospitals in pa...
Only a few studies have addressed the cost-effectiveness of pharmacogenetics interventions in health...
Current guidelines recommend pre-therapeutic UGT1A1 genotyping to guide irinotecan dosing, but the u...
Only a few studies have addressed the cost-effectiveness of pharmacogenetics interventions in health...
Objective. To determine whether prospective testing forHLA-B*58:01, as a strategy to preve...
BACKGROUND: Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), caused by allopurin...
The overall goal of this study was to provide evidence for the clinical validity of nine genetic var...
BackgroundChemotherapy-induced nausea and vomiting are concerning adverse events resulting from canc...
Objectives The study aims at evaluating the economic evidence related to testing for genetic varian...
BackgroundChemotherapy-induced nausea and vomiting are concerning adverse events resulting from canc...